See more : CPS Technologies Corporation (CPSH) Income Statement Analysis – Financial Results
Complete financial analysis of Aprogen Medicines Inc. (007460.KS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aprogen Medicines Inc., a leading company in the Industrial – Machinery industry within the Industrials sector.
- The Very Good Food Company Inc. (VGFC) Income Statement Analysis – Financial Results
- Jupiter Gold Corporation (JUPGF) Income Statement Analysis – Financial Results
- Wai Chun Bio-Technology Limited (0660.HK) Income Statement Analysis – Financial Results
- Ruida Futures Co., Ltd. (002961.SZ) Income Statement Analysis – Financial Results
- Pacifico Acquisition Corp. (PAFO) Income Statement Analysis – Financial Results
Aprogen Medicines Inc. (007460.KS)
About Aprogen Medicines Inc.
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 1971 and is based in Seongnam-si, South Korea.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 150.58B | 78.35B | 141.25B | 127.14B | 78.25B | 51.05B | 44.90B | 54.84B | 65.93B | 76.54B | 103.04B | 170.69B | 354.37B | 232.26B | 226.33B | 273.13B | 129.42B |
| Cost of Revenue | 114.77B | 72.20B | 110.00B | 92.68B | 58.89B | 41.86B | 40.60B | 44.90B | 54.88B | 62.02B | 94.13B | 139.20B | 338.82B | 202.01B | 189.44B | 233.98B | 104.53B |
| Gross Profit | 35.81B | 6.15B | 31.25B | 34.46B | 19.36B | 9.18B | 4.30B | 9.94B | 11.05B | 14.52B | 8.91B | 31.49B | 15.54B | 30.25B | 36.89B | 39.15B | 24.90B |
| Gross Profit Ratio | 23.78% | 7.85% | 22.12% | 27.11% | 24.74% | 17.99% | 9.57% | 18.13% | 16.76% | 18.97% | 8.65% | 18.45% | 4.39% | 13.02% | 16.30% | 14.33% | 19.24% |
| Research & Development | 42.82B | 38.56B | 1.98B | 1.03B | 1.87B | 4.38B | 407.05M | 359.75M | 0.00 | 0.00 | 0.00 | 0.00 | 543.26M | 1.07B | 1.88B | 1.84B | 1.37B |
| General & Administrative | 20.83B | 29.09B | 3.88B | 3.93B | 2.19B | 153.46M | 152.47M | 152.80M | 132.37M | 317.65M | 445.05M | 1.07B | 3.16B | 2.37B | 2.29B | 2.28B | 1.70B |
| Selling & Marketing | 20.01B | 11.88B | 11.81B | 8.13B | 4.64B | 467.50M | 197.20M | 169.54M | 188.94M | 334.58M | 703.62M | 1.95B | 12.20B | 5.30B | 4.73B | 4.24B | 3.60B |
| SG&A | 40.84B | 40.96B | 15.68B | 12.06B | 6.83B | 620.96M | 349.68M | 322.34M | 321.31M | 652.22M | 1.15B | 3.02B | 15.36B | 7.66B | 7.02B | 6.52B | 5.30B |
| Other Expenses | 41.01B | 40.98B | 16.26B | 17.40B | 8.09B | 207.36M | 661.20M | 407.07M | 3.00B | 6.43B | 6.60B | 1.43B | -6.93B | -9.22B | 336.95M | -372.13M | 38.45M |
| Operating Expenses | 124.67B | 120.51B | 33.92B | 30.49B | 16.79B | 7.61B | 2.47B | 4.88B | 5.04B | 5.91B | 4.50B | 7.49B | 37.19B | 19.78B | 19.43B | 17.95B | 13.35B |
| Cost & Expenses | 239.44B | 192.70B | 143.92B | 123.17B | 75.68B | 49.47B | 43.07B | 49.77B | 59.92B | 67.93B | 98.63B | 146.68B | 376.02B | 221.79B | 208.87B | 251.94B | 117.88B |
| Interest Income | 3.68B | 3.03B | 16.27B | 10.92B | 4.54B | 2.96B | 164.02M | 12.38M | 51.77M | 3.19B | 191.49M | 546.20M | 1.99B | 4.13B | 3.54B | 2.44B | 1.47B |
| Interest Expense | 1.76B | 9.91B | 11.42B | 5.23B | 9.15B | 20.71B | 1.53B | 1.88B | 3.81B | 6.20B | 8.65B | 12.36B | 16.03B | 12.62B | 9.91B | 8.72B | 6.08B |
| Depreciation & Amortization | 29.07B | 28.35B | 3.76B | 3.76B | 2.87B | 263.53M | 217.86M | 2.19B | 2.30B | 2.36B | 2.48B | 19.49B | 16.42B | 6.19B | 5.68B | 4.64B | 3.69B |
| EBITDA | -65.54B | -76.15B | -70.54B | -20.35B | 40.82B | 741.43M | 4.59B | 7.39B | 9.50B | 21.00B | 9.17B | 43.92B | -21.91B | 7.15B | 22.34B | 24.73B | 18.30B |
| EBITDA Ratio | -43.52% | -83.18% | -4.53% | 7.81% | 57.11% | -1.61% | 9.98% | 13.70% | 14.27% | 27.95% | 12.97% | 25.95% | -6.18% | 2.85% | 9.91% | 9.05% | 12.77% |
| Operating Income | -88.87B | -114.35B | -2.67B | 5.63B | 41.44B | 1.57B | 1.83B | 5.06B | 6.02B | 8.60B | 4.41B | 24.00B | -21.65B | 10.46B | 17.46B | 21.19B | 11.54B |
| Operating Income Ratio | -59.02% | -145.95% | -1.89% | 4.42% | 52.96% | 3.08% | 4.08% | 9.24% | 9.12% | 11.24% | 4.28% | 14.06% | -6.11% | 4.51% | 7.71% | 7.76% | 8.92% |
| Total Other Income/Expenses | -6.37B | -1.26B | -37.51B | -43.09B | 14.36B | -23.58B | -910.24M | -1.74B | -2.62B | 3.84B | -6.67B | -11.93B | -62.19B | -22.13B | -10.71B | -12.38B | -3.01B |
| Income Before Tax | -95.24B | -115.61B | -9.18B | -39.12B | 16.92B | -22.01B | 1.16B | 3.32B | 3.39B | 12.45B | -2.27B | 12.07B | -83.84B | -11.66B | 6.74B | 8.81B | 8.53B |
| Income Before Tax Ratio | -63.25% | -147.56% | -6.50% | -30.77% | 21.63% | -43.11% | 2.59% | 6.06% | 5.14% | 16.26% | -2.20% | 7.07% | -23.66% | -5.02% | 2.98% | 3.23% | 6.59% |
| Income Tax Expense | 2.04B | 473.80M | 3.32B | -6.45B | -1.40B | 2.91B | -1.18B | 914.57M | 1.09B | 10.43B | 1.32B | 486.10M | -2.80B | 2.86B | 2.21B | -2.35M | 1.54B |
| Net Income | -55.62B | -116.08B | -12.50B | -32.67B | 18.33B | -32.11B | 2.34B | 2.41B | 3.39B | 12.45B | -51.13B | -12.07B | -52.55B | -13.63B | 4.40B | 9.75B | 6.91B |
| Net Income Ratio | -36.94% | -148.16% | -8.85% | -25.69% | 23.42% | -62.90% | 5.21% | 4.39% | 5.14% | 16.26% | -49.62% | -7.07% | -14.83% | -5.87% | 1.94% | 3.57% | 5.34% |
| EPS | -235.50 | -1.73K | -194.12 | -577.78 | 402.11 | -1.90K | 350.93 | 440.91 | 863.83 | 3.58K | -17.17K | -7.58K | -39.77K | -10.33K | 3.44K | 8.07K | 7.84K |
| EPS Diluted | -235.50 | -1.72K | -194.12 | -577.78 | 402.11 | -1.90K | 350.93 | 395.92 | 698.86 | 1.99K | -17.17K | -7.58K | -39.77K | -10.33K | 3.37K | 8.07K | 7.84K |
| Weighted Avg Shares Out | 236.17M | 67.06M | 64.39M | 56.54M | 45.57M | 16.94M | 6.66M | 5.46M | 3.93M | 3.48M | 2.98M | 1.59M | 1.32M | 1.32M | 1.28M | 1.21M | 881.23K |
| Weighted Avg Shares Out (Dil) | 236.17M | 67.46M | 64.39M | 56.54M | 45.57M | 16.94M | 6.67M | 6.08M | 4.85M | 6.26M | 2.98M | 1.59M | 1.32M | 1.32M | 1.30M | 1.21M | 881.23K |
Source: https://incomestatements.info
Category: Stock Reports